Acute Iliofemoral DVT

More documents

Recommendations

Info

CaVenT Study • Open, multicenter, prospective, randomized study comparing conventional treatment for DVT with catheter-directed therapy in addition to conventional treatment. • Inclusion criteria: (a) age 18 – 75 years; (b) onset of symptoms < 21 days; (c) objectively verified iliofemoral or proximal femoral DVT; and (d) informed consent. Enden, et al., J Thromb Haemost, 2009; 7: 1268-75.
CaVenT Study: Efficacy Catheter-directed thrombolysis (N=50) Standard therapy (N=53) P-value Iliofemoral patency* 32 (64%) 19 (35.8%) 0.004 Functional venous obstruction* Femoral venous insufficiency* * After six months of therapy. 10 (20%) 26 (49.1%) 0.004 30 (60%) 35 (66%) 0.53 Enden, et al., J Thromb Haemost, 2009; 7: 1268-75.
Page 1 and 2: Medical Management of Acute Iliofem
Page 3 and 4: Great Debates
Page 9 and 10: Audience Response
Page 11 and 12: Anticoagulation vs. No Anticoagulat
Page 13 and 14: ACCP Guidelines: Initial DVT Therap
Page 15 and 16: ACCP Guidelines: Warfarin Therapy 1
Page 17 and 18: Poor Management of Warfarin and Rec
Page 19 and 20: Medical Management of Acute Iliofem
Page 21 and 22: New Anticoagulants: Dabigatran •
Page 23 and 24: Limitations of the New Anticoagulan
Page 25 and 26: Iliofemoral DVT • Patients with i
Page 27 and 28: Post-thrombotic Syndrome • Proxim
Page 29 and 30: Compression Stockings and PTS • 1
Page 31 and 32: Systemic Thrombolytic Therapy Varia
Page 33: Medical Management of Acute Iliofem
Page 37 and 38: ACCP Guidelines 1.9.1 In selected p
Page 39: Conclusions • Anticoagulant thera

Acute Iliofemoral DVT

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?